TSHA Taysha Corp: Bozor kapitallashuvining balans qiymatiga nisbati
Taysha Gene Therapies (TSHA) kompaniyasi loyihalar kapitaliga tayanadi, chunki barqaror daromad hali shakllanmagan va ishlanmalar sinov bosqichida qolmoqda. Biroq, noyob patologiyalarni davolashdagi muvaffaqiyatlar monopol narx belgilash imkoniyati orqali superfoydalar olishga yo'l ochadi. Ushbu grafik aksiyalar narxi dinamikasini 3.50 sifatida tasvirlaydi. Taysha Gene Therapies (TSHA) neyrodegenerativ buzilishlarga e'tibor qaratgan holda, maqsadli gen yetkazib berish tizimlari va "orphan drug" maqomi bilan bog'liq soliq imtiyozlaridan foydalanadi.
%20Kapitallashuvning%20balans%20qiymatiga%20nisbati&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_TSHA_-_Taysha-Gene-Therapies_-_Capitalization-to-Book-Value-Ratio "TSHA: tayshagtx.com Bozor qiymatining balans qiymatiga nisbati 04.07.2022 - 01.11.2026 | 👁️GURU.Markets👁️")
Taysha Gene Therapies Inc - tahliliy kesimlar va asosiy koʻrsatkichlar (TSHA)
- aksiya kursi va ekspertlarning narx prognozi:
- kompaniya aksiyalari kapitallashuvi ma'lumotlari:
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Umumiy qarzning xususiy kapitalga nisbati Taysha Gene Therapies|TSHA - Uzoq muddatli kreditlarning kapitalga nisbati|Qisqa muddatli qarzning kapitalga nisbati Taysha|TSHA - Kompaniyaning jamlangan qarzlari|Qarzning balans qiymatiga nisbati Taysha|TSHA - Uzoq muddatli qarz|Kompaniyaning qisqa muddatli qarzi Taysha Gene Therapies|Tezkor likvidlik koeffitsiyenti tayshagtx.com
- foyda va bozor multiplikatorlari tafsilotlari:
Kompaniyaning dastlabki tahlili:Taysha Gene Therapies, TSHA
Taysha Gene Therapies (TSHA) kompaniyasining xalqaro patent himoyasiga bog'liqligi va dori vositalarini transchegaraviy ro'yxatdan o'tkazishning murakkabliklari uning nomoddiy aktivlarining bozor qiymatiga bevosita ta'sir ko'rsatadi. Ushbu ko'rsatkich bozor narxini biznesning sof aktivlari bilan solishtirib, kelajakdagi o'sish uchun premiumni yoki past baholanish xavfini aks ettiradi, bu esa kompaniyaning P/BV koeffitsiyenti o'zgarishlari orqali strategik rivojlanish vektorini aniqlash imkonini beradi.
Raqobatdosh kompaniyalar tahlili
TEM: Bozor kapitallashuvining balans qiymatiga nisbati|qiagen.com (QGEN) - Bozor kapitallashuvining balans qiymatiga nisbati|IONS (Ionis) - Bozor kapitallashuvining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati RGEN (Repligen Corp)|Bozor qiymatining balans qiymatiga nisbati Avidity (RNA)|CRISPR - Kapitallashuvning balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati WGS (GeneDx Holdings Corp.)|Bozor kapitallashuvining balans qiymatiga nisbati ultragenyx.com RARE|BEAM: Kapitallashuvning sof aktivlarga nisbati|Sarepta Therapeutics - Bozor kapitallashuvining balans qiymatiga multiplikatori|TWST: Bozor kapitallashuvining balans qiymatiga nisbati|10x (TXG) - Bozor kapitallashuvining balans qiymatiga nisbati|Kapitallashuvning sof aktivlarga nisbati NTLA|Bozor qiymatining balans qiymatiga koeffitsiyenti stoketherapeutics.com STOK|Bozor qiymatining balans qiymatiga nisbati BioLife Solutions (BLFS)|Balans qiymatiga nisbatan bozor kapitallashuvi Wave Life Sciences Ltd|Bozor kapitallashuvining balans qiymatiga nisbati MAZE (Maze Tx)|Balans qiymatiga nisbatan bozor qiymati SION|Prime Medicine, Inc. - Bozor kapitallashuvining balans qiymatiga nisbati|QURE - Bozor kapitallashuvining balans qiymatiga nisbati|MGTX (MeiraGTx) - Kapitallashuvning sof aktivlarga nisbati|REGENXBIO Inc - Balans qiymatiga nisbatan bozor qiymati|SLDB (Solid Bio) - Bozor kapitallashuvining balans qiymatiga nisbati|OCGN - Bozor qiymatining xususiy kapitalga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati PACB|BNTC - Bozor qiymatining balans qiymatiga koeffitsiyenti|Bozor qiymatining balans qiymatiga nisbati Design Therapeutics, Inc. DSGN|RCKT: Kapitallashuvning balans qiymatiga nisbati|4D Molecular Therapeutics Inc - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti Lexeo Therapeutics|KRRO (korrobio.com) - Kapitallashuvning sof aktivlarga nisbati|editasmedicine.com - Balans qiymatiga nisbatan bozor qiymati|Kapitallashuvning sof aktivlarga nisbati SLN|PRQR (ProQR Therapeutics NV) - Bozor kapitallashuvining balans qiymatiga multiplikatori|Bozor kapitallashuvining balans qiymatiga nisbati CDXS|SGMO (Sangamo BioSciences) - Balans qiymatiga nisbatan bozor qiymati|Bozor kapitallashuvining balans qiymatiga nisbati NAUT (Nautilus Bio)|metagenomi.co (MGX) - Bozor qiymatining balans qiymatiga koeffitsiyenti|DTIL - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati GBIO (Generation Bio Co.)|BOLD: Bozor kapitallashuvining balans qiymatiga nisbati|Exicure (XCUR) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati Imunon Inc|RXi Pharmaceuticals - Sof aktivlarga nisbatan bozor kapitallashuvi|Bozor kapitallashuvining balans qiymatiga nisbati MBIO|Balans qiymatiga nisbatan bozor kapitallashuvi transcodetherapeutics.com|Bozor kapitallashuvining balans qiymatiga nisbati BNGO (Bionano Genomics)|Applied DNA Corp (APDN) - Bozor qiymatining balans qiymatiga koeffitsiyenti|BLUE - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor kapitallashuvi ImmunoPrecise Antibodies IPA|OMGA (Omega Therapeutics, Inc.) - Kapitallashuvning sof aktivlarga nisbati|OMIC: Bozor kapitallashuvining balans qiymatiga multiplikatori|Bozor qiymatining balans qiymatiga nisbati Regulus Therapeutics Inc|Syros Pharmaceuticals, Inc (SYRS) - Balans qiymatiga nisbatan bozor kapitallashuvi|Bozor kapitallashuvining balans qiymatiga nisbati TBIO|TCON (traconpharma.com) - Balans qiymatiga nisbatan bozor qiymati|Bozor kapitallashuvining balans qiymatiga nisbati UBX (Unity Biotechnology, Inc.)